Cargando…
Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma
The selection of effective therapeutic agents is critical for improving the survival of patients with renal cell carcinoma (RCC). The aim of the present study was to develop an ex vivo drug testing assay using patient-derived tumor organoid (TO) cultures. For this purpose, surgical tumor specimens w...
Autores principales: | Kazama, Akira, Anraku, Tsutomu, Kuroki, Hiroo, Shirono, Yuko, Murata, Masaki, Bilim, Vladimir, Ugolkov, Andrey, Saito, Kazuhide, Tomita, Yoshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424486/ https://www.ncbi.nlm.nih.gov/pubmed/34468011 http://dx.doi.org/10.3892/or.2021.8177 |
Ejemplares similares
-
Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2022) -
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells
por: Shirono, Yuko, et al.
Publicado: (2023) -
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
por: Kuroki, Hiroo, et al.
Publicado: (2021) -
Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020) -
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019)